Naltrexone-bupropion for managing overweight and obesity: Notice of appeal

NICE has received one appeal against the Final Appraisal Determination on the above technology from the following organisation:


  • Orexigen Therapeutics Ireland, Limited


The appeal panel will convene on Friday 27 October 2017 at NICE, 10 Spring Gardens, London SW1A 2BU to hear oral representations from the appellants.


Members of the public, including consultees and commentators for this appraisal, and the press, may request to attend the hearing. The number of places for observers is constrained by the venue, and priority will be given to members of the public who are not employed by the appellant. There are 15 places available for this appeal hearing.


Where possible, requests to attend should be made using the form that will be available on the Institute’s website.  This form will be available from Friday 25 August 2017 only. The web site registration will allow requests to attend to be granted on a first-come, first-served basis. The registration period for this appeal will end at 5pm Monday 11 September 2017. Further details relating to public attendance at this appeal are available on the same webpage as above.


A limited number of places at the appeal hearing will be reserved for members of the public who do not have access to the internet. These places should be applied for in writing, addressed to the Appeals Coordinator, to arrive before 5pm on Monday 11 September 2017. Written requests to attend will also be granted on a first-come, first-served basis.